Kinvard Bio Inc. has been awarded US$2.7 million follow-on non-dilutive funding from CARB-X. The funding will support advanced lead optimization efforts for developing ribosome-targeting antibiotics. Kinvard Bio may be eligible for additional funding upon meeting certain milestones

Carb X

Kinvard Bio Inc. is a biotechnology company pioneering a next-generation class of broad-spectrum antibiotics. It focuses on developing differentiated ribosome-targeting antibiotics for serious drug-resistant infections, integrating rational drug design with proprietary synthetic chemistry. The company's pipeline includes novel oral and intravenous antibiotics aimed at treating difficult-to-manage bacterial infections. 

http://www.kinvardbio.com/

Therapeutics

Biotechnology

Raleigh

Kinvard Bio

Kinvard Bio Inc. has secured $2.7 million in follow-on non-dilutive funding from CARB-X to develop next-generation antibiotics aimed at fighting drug-resistant infections.

Kinvard Bio Inc. has secured $2.7 million in follow-on non-dilutive funding from CARB-X to develop next-generation antibiotics aimed at fighting drug-resistant infections.

Investors

Description

Company Information

Related People

Funding Insights

Kinvard Bio Inc. has secured $2.7 million in follow-on non-dilutive funding from CARB-X to develop next-generation antibiotics aimed at fighting drug-resistant infections.

Investors

Description

.css-1v6jzuu{--tw-text-opacity:1;color:rgba(75, 85, 99, var(--tw-text-opacity));}Company Information

Related People

Funding Insights

Company Information